{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:23:20Z","timestamp":1791843800345,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.humpath.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T01:14:27Z","timestamp":1694222067000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor"],"prefix":"10.1016","volume":"141","author":[{"given":"Emanuela","family":"D'Angelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Felicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiamma","family":"Buttitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2023.08.010_bib1","series-title":"Female genital tumours","year":"2020"},{"key":"10.1016\/j.humpath.2023.08.010_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PAS.0b013e318188b84c","article-title":"Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas","volume":"33","author":"Cuatrecasas","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/modpathol.2016.82","article-title":"Morphologic correlates of molecular alterations in extrauterine M\u00fcllerian carcinomas","volume":"29","author":"Ritterhouse","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","article-title":"PARP inhibitors in ovarian cancer","volume":"27","author":"Ledermann","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2023.08.010_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2023.08.010_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00000478-200209000-00002","article-title":"Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion","volume":"26","author":"Prat","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib11","unstructured":"myChoice HRD Technical Specifications Effective Date: June 2017, Myriad Genetics, Accessed May 2022. https:\/\/myriad-web.s3.amazonaws.com\/myChoice\/downloads\/myChoiceHRDTechSpecs.pdf."},{"key":"10.1016\/j.humpath.2023.08.010_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.08.010_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian\u00a0cancer: mutation prevalence and precise risk estimates based on a pooled analysis of \u223c30,000 cases","volume":"13","author":"Suszynska","year":"2020","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.humpath.2023.08.010_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e17599","article-title":"A deep learning\u00a0solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: evaluation of the analytical performance","volume":"40","author":"Buisson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.08.010_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PGP.0b013e31824d7445","article-title":"Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor","volume":"31","author":"Ali","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2023.08.010_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2023.08.010_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.08.010_bib18","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","article-title":"Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","volume":"10","author":"Takaya","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2023.08.010_bib19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2023.08.010_bib20","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (adp-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.08.010_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts' consensus group. European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2023.08.010_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12957-020-01931-7","article-title":"The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2020","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.humpath.2023.08.010_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102040","article-title":"Incorporating parp-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II\/III randomized controlled trials","volume":"87","author":"Ruscito","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.humpath.2023.08.010_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000480","article-title":"Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?","volume":"4","author":"Pellegrino","year":"2019","journal-title":"ESMO Open"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723001855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723001855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:41:31Z","timestamp":1758645691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817723001855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"alternative-id":["S0046817723001855"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2023.08.010","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}